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Appendix
We scored the modifications of joints according to
Melchiorre’s US score (13) as follows:
1. Joint effusion: (absent = 0; small = 1; moder-
ate = 2; large = 3).
2. Synovial hypertrophy with flags on PDUS (<3
flags = 1; >3 flags = 2).
3. Synovial hypertrophy without flags on PDUS:
thickness measured in mm (score 1: <1.5 mm;
score 2: 1.5–2.5 mm; score 3: >2.5 mm).
4. Fibrous septa: absent = 0; present = 1.
5. Haemosiderin deposition: it appears as a diffuse
hyperechoic signal (absent = 0; small = 1; moder-
ate = 2; large = 3).
6. Remodelling of bone: defined as joint surface irregu-
larity and incongruence (absent = 0; present = 1).
7. Osteophytes: defined as marginal hypertrophic
bone formation (absent = 0; present = 1).
8. Bone erosion: defined as a cortical ‘break’ with an
irregular shape seen in the longitudinal or in the
coronal plane (absent = 0; present = 1).
9. Cartilage damage: absent = 0; hyperechogenic-
ity = 1; irregular profile = 2; calcification = 3.
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Prophylactic replacement therapy is the cornerstone of
treatment in severe haemophilia. Regular infusions
with clotting factor concentrate have been proven
effective to prevent bleeding, subsequent (joint) dam-
age, and positively affect the impact of haemophilia
on daily life [1]. Patients or parents of younger
patients learn to infuse clotting factor concentrate in a
peripheral vein (i.v.) or a central venous access device
(CVAD) [2].
As even a single bleed may cause irreversible damage,
prophylaxis requires lifelong adherence and well-devel-
oped self-management skills [3]. The UKHCDO guide-
lines (United Kingdom Haemophilia Centre Doctors
Organisation) described that competence in venous
access technique as an important aspect of successful
prophylaxis [4]. In the Netherlands, these skills are
learned in an individualized training course with an
average of eight sessions (IQR: 4–14 visits) [2]. After
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passing the exam, patients or parents are qualified to
perform intravenous treatment independently [2,5].
There are no follow-up sessions and the quality of the
procedure is never formally evaluated. In addition,
many patients stated that they did not ‘have enough
time’ to infuse in the morning [6], leading to non-
adherence. However, the time needed for self-infusion
has never been studied. The aim of this study was to
quantify adherence to (self) infusion guidelines [5] as
well as the time needed for prophylaxis in haemophilia.
This study comprised a cross-sectional observational
study, which was embedded in the nursing consulta-
tion of three large Dutch Haemophilia Treatment
Centres (Utrecht, Amsterdam and Rotterdam).
Patients of all ages with a congenital clotting factor
deficiency using prophylaxis with a minimum frequency
of once weekly were eligible for inclusion. Conve-
nience sampling was used: during outpatient clinic vis-
its, patients were asked to administer their regular
prophylaxis, while nurses observed the quality and
duration of self-infusion procedure according to a
checklist. The checklist was based on the Dutch guide-
lines for learning i.v. or CVAD infusion with a non-
sterile (1 centre) and sterile approach (2 centres) [5].
Concomitantly, the time needed for self-infusion was
recorded with a stopwatch and comprised the entire
procedure from the start of preparation of the materi-
als to completion of the infusion diary. Patient charac-
teristics collected were: year and month of birth, the
person performing the procedure (patient or parent),
diagnosis (haemophilia A, B or von Willebrand type
III), current treatment (prescribed frequency and dose),
venous access route (i.v. or CVAD) and certification
for (self-) infusion (present/ absent, including date).
Descriptive statistics were performed separately for
i.v. and CVAD infusion. Due to the skewed distribu-
tions, the data was analysed using the Mann–Whitney
U-test (significant at P < 0.05). All analyses were per-
formed with SPSS software, version 20 [IBM SPSS
Statistics 20 (SPSS Inc., Chicago, IL, USA)].
Overall, 161 infusion procedures in 132 patients
or parents were evaluated in the three centres
(Utrecht n = 94, Amsterdam n = 57 and Rotterdam
n = 10), comprising 48% of the total population on
prophylaxis in these centres. Patient characteristics
are presented in Table 1. Patients learning to self-
infuse were excluded from analysis (n = 26), as infu-
sion took significant longer (13:00 min, P > 0.001).
For 31/ 161 procedures, only time assessment was
performed. The patients had a median age of
13.7 years (Interquartile (IQR): 9.7-23.3). The major-
ity of the patients were diagnosed with haemophilia
A (84%), and the majority had severe haemophilia
(91%). Most patients (47%) followed a prophylactic
regimen of 3.0 times per week with 1000 IU per
infusion.
Table 1. Patient and treatment characteristics.*




Three or more 16
Age (median, IQR) 13.7 years (9.7–23.3)
Diagnosis
Haemophilia A 135 (84%)
Haemophilia B 16 (10%)
von Willebrand disease 10 (6%)
Severity
Severe haemophilia 146 (91%)
Moderate haemophilia 7 (4%)





Frequency prophylaxis (median, range) 3.0 (2–7)
Dose prophylaxis (median, range) 1000 (250–3000)
i.v., intravenous; CVAD, central venous access device.
Values are reported as frequencies or medians (interquartile range).
*26 patients were excluded from final analysis because they were engaged
in learning self-infusion.
Table 2. Evaluation of quality and timing of infusion procedures.
Activity
i.v. Central venous access device (CVAD)
% Correct performance
i.v. (n = 116*)
Median time
i.v. (mm:ss/ n = 147)
% Correct performance
CVAD (n = 14)
Median time
CVAD (mm:ss/ n = 14)
Preparing materials 89 00:37 100 01:03
Washing hands 54† 00:40 69 00:42
Check product, date, dose 51 00:12 77 00:20
Dissolving product 100 02:15 100 03:05





CVAD: Non-sterile approach (n = 5)





Safe disposal of needle 95 00:38 100 01:00
Complete infusion diary after infusion 40† 00:47 54 00:31
Total time (range) – 06:40 (03:00–23:33) – 11:07 (06:36–30:00)
i.v., intravenous; CVAD, central venous access device.
Values are proportions and medians (minutes: seconds).
*During 31 infusions, the checklist for self-infusion was not fully completed and excluded in this section.
†Parents performed this procedure significant more than the patients.
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The mean experience with self-infusion was
4.9 years (range 0–25.6 years). The evaluation of the
quality and timing of infusion procedures is shown
in Table 2. Obtaining venous access and administrat-
ing CFC were performed correctly by all patients
and parents with 96% succeeding at the first
attempt. In contrast, only half the patients/ parents
washed their hands before infusing and completed
the infusion diary. For i.v. infusion, 147 procedures
were performed by 85 patients and 49 parents in a
median of 6.7 min (range 3–23.5 min). Most time
was needed for the infusion procedure itself (min
2:29). Parents needed slightly longer for the proce-
dure (median 8 min) than patients who performed
self-infusion (median 6.5 min), yet, this difference did
not reach statistical significance (P = 0.23). In total,
65% washed their hands according to procedure,
including a higher proportion of parents (89%,
P = 0.001) than patients (53%). Verifying the correct
product, expiry date and correct dose before adminis-
tration was not actively done by 47% of the patients
and parents. In contrast, all performed the prepara-
tion of the clotting factor concentrate correctly. The
majority of the patients and parents (95%) disposed
the needle according to the protocol, yet, registration
in the infusion diary after infusion was forgotten by
majority of patients (60%). Parents completed the
infusion diary significantly more often than patients
(67% vs. 35%, P = 0.001). Patients who perform for
a longer period self-infusion (≥40 years of age) were
not more adherent to the infusion procedures
than patients who recently started with self-infusion
(13–25 years old).
For CVAD infusion, 14 infusions performed by 10
parents were evaluated. The median total time needed
for CVAD infusion was 11.1 min (range 6.5–30 min).
Before preparation of the materials, 69% of parents
washed their hands and 77% checked the product
name, date and dose. All parents dissolved the CFC
correctly (3 min); this took slightly longer than for i.v.
infusion, due to preparation of extra solvents (heparin,
water). CVAD infusion according to the non-sterile
approach (n = 5) took a median of 2 min and 3.5 min
(n = 8), according to the sterile approach. All parents
removed the needle and disposed it according to pro-
tocol. Registration of the infusion in a diary direct
after the infusion was performed by 54%.
Some limitations of this study should be discussed.
Convenience sampling led to selection of relatively
younger patients (median 13.7 years), as young chil-
dren visited the outpatient clinic more often than
adult patients. In addition, the number of CVAD pro-
cedures assessed was limited (n = 14) due to practical
reasons; CVAD infusion procedures usually required
the assistance of two nurses (one observer and one
holding the child), which was difficult to combine
with the study assessment. All assessments were per-
formed in the outpatient clinic and not in the home
setting: blood sampling was sometimes required.
Nurses tried to emphasize to perform the procedure
just the same as at home and stopped the stopwatch
during blood withdrawal.
These findings were compared to a Dutch study
assessing the effect of an e-learning program on self-
infusion by Mulders et al. [7]. This study reported
equal proportions of diary keeping (40% in both stud-
ies), but higher rates of hand washing (75% vs. 45%
in this study). After following the e-learning pro-
gramme, performance significantly improved to 75%
(increase of 27%). We hypothesize that regular check-
ups of the quality of the infusion procedure, including
reminders for washing hands and completing the infu-
sion diary, could help to maintain the quality of the
procedure. Patients did not actively check the product
name, dose and date of expiry, before administration.
Most patients check the whole batch after receiving
this at the pharmacy. The time needed for the proce-
dures was not studied before.
In conclusion, self-infusion of prophylaxis takes
only a little time: a median of 6.7 min for i.v. infusion
or 11.1 min for CVAD infusion. Adherence to the
essential infusion activities (preparing and injection of
CFC) were generally performed correctly. Washing
hands was forgotten by 46% of the patients/parents
and completion of the infusion diary was skipped by
60%. Therefore, standard follow-up every other year
to check correct performance of self-infusion may
improve these aspects of home treatment.
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PBAC score: an easy-to-use tool to predict coagulation
disorders in women with idiopathic heavy menstrual
bleeding
S. HALIMEH, H. ROTT and G. KAPPERT
Coagulation Centre Rhine-Ruhr Medical Thrombosis and Haemophilia Treatment Centre and Specialized Laboratory for
Coagulation Disorders/Haemophilia, Duisburg, Germany
Women with inherited bleeding disorders suffer signif-
icant morbidity and impaired quality-of-life associated
with heavy menstrual-related bleeding [1]. Heavy
menstrual bleeding (HMB), also referred to as menor-
rhagia, is defined as uterine bleeding that lasts for
>7 days or blood loss >80 mL per menstrual cycle [2].
The wide variation in what constitutes ‘normal’ bleed-
ing makes identifying patients with HMB difficult for
both clinicians and patients [1]. Indeed some women,
especially those from families with hereditary bleeding
disorders, do not realize they have HMB so do not
seek medical advice for their condition.
HMB is often a presenting symptom of coagulation
disorders, and may be the only bleeding symptom
[3]. An increased prevalence of von Willebrand dis-
ease (VWD) has been observed in women with HMB
(13% [95% CI 11–16%] compared with 0.8–1.3%
in the general population) [4] and it has been pro-
posed that mild platelet function defects are even
more common, with ~50% diagnosed with platelet
aggregation defects compared with a control fre-
quency of 17.3% [5].
A semi-objective method to quantify menstrual
blood loss is the alkaline haematin technique, which
requires the collection of all tampons or sanitary tow-
els for laboratory analysis [6]. Although the most
accurate method, it is too time-consuming and expen-
sive for routine clinical practice. Alternatives include
collecting and weighing all products used or the use of
vaginal cups for menstrual collection; however, these
methods can encounter problems with fluid evapora-
tion and/or leakage. Another method is the pictorial
blood assessment chart (PBAC) Score [7]. This method
records the number of tampons or towels used and
the degree to which they are stained with blood. A
validation study found that the PBAC Score was supe-
rior to a woman’s subjective assessment of menstrual
blood loss, with a positive predictive value of 85.9%
[8]. Additionally, a comparison of PBAC Score with
the alkaline haematin method found a significant cor-
relation between the two [9]. PBAC Scores >100 have
been confirmed in the majority of women diagnosed
with coagulopathic disorders [10].
We performed a retrospective analysis to assess
whether the amount of menstrual blood loss, deter-
mined using the PBAC Score, can be used as a predic-
tor for the presence of coagulation disorders in
women with idiopathic HMB. All patients with a his-
tory of HMB referred to our coagulation centre
between September 2011 and October 2013 were
included. Known causes of gynaecological and
endocrinological HMB had been ruled out by the
patients’ gynaecologists, and patients were not receiv-
ing any treatment that may have affected the PBAC
Score, such as tranexamic acid, desmopressin or factor
concentrate. Women without a history of HMB were
recruited from among the patients’ family, friends and
associates as a control group; patients were not age-
matched, but were similar in age. None of the partici-
pants were on oral contraceptives. Informed consent
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